InMed Announces Results of 2022 Annual General Meeting
15 Dezembro 2022 - 8:17PM
InMed Pharmaceuticals Inc. (“
InMed” or the
“
Company”) (
Nasdaq: INM), a
leader in the pharmaceutical research, development and
manufacturing of rare cannabinoids and cannabinoid analogs, today
confirmed that, at its annual general meeting of shareholders held
on December 15, 2022 (the “Meeting”), all of the matters put
forward before shareholders for consideration and approval as set
out in InMed’s notice of meeting and management information
circular, dated October 28, 2022, were approved by the
shareholders. In particular, shareholders approved the election of
all director nominees to hold office until the next annual meeting
of shareholders or until their successors are elected or appointed.
Results of the vote for the election of directors at the Meeting
are set out as follows:
Director |
Votes For |
|
Withheld Votes |
Number |
Percentage |
|
Number |
Percentage |
Eric A. Adams |
159,223 |
94.90 |
% |
|
8,559 |
5.10 |
% |
Andrew Hull |
158,282 |
94.34 |
% |
|
9,500 |
5.66 |
% |
Janet Grove |
162,246 |
96.70 |
% |
|
5,536 |
3.30 |
% |
Bryan Baldasare |
160,764 |
95.82 |
% |
|
7,018 |
4.18 |
% |
Nicole Lemerond |
162,174 |
96.66 |
% |
|
5,608 |
3.34 |
% |
InMed filed a report of voting results on SEDAR
at www.sedar.com on December 15, 2022.
About InMed: InMed
Pharmaceuticals is a global leader in the research, development and
manufacturing of rare cannabinoids, including clinical and
preclinical programs targeting the treatment of diseases with high
unmet medical needs. We also have significant know-how in
developing proprietary manufacturing approaches to produce
cannabinoids for various market sectors. For more information,
visit www.inmedpharma.com.
Investor Contact: Colin ClancyVice President,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: being a global leader in the
manufacturing and development of rare cannabinoids and delivering
new treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
InMed Pharmaceuticals (NASDAQ:INM)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024